Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia

项目摘要 儿童近视，也被称为近视，是一种眼睛状况，在这种情况下，一个人不能走远 将物体对准合适的焦点。它是世界上导致视力障碍的主要原因。估计的经济 未经纠正的屈光不正的影响估计是全球国内生产总值的2020亿美元的损失。 近视和高度近视的患病率正以惊人的速度在全球范围内增长，而且增幅显著 与高度近视相关的病理状况导致视力损害的风险，包括视网膜 损伤、白内障和青光眼。2000年，近视的患病率在任何地区都不超过50%。 但是，如果目前的趋势继续下去，到2050年，57%的国家的≥患病率将达到50%。 我们提出了一种新的局部滴眼液，IVMED-85，用于治疗近视。这是一种一流的药物 上调赖氨酰氧化酶，在药理上诱导巩膜和角膜的交联化和硬化。 我们的中心假设是，局部使用铜滴眼液治疗可以实现非侵入性、简单使用、 通过药物诱导巩膜和角膜胶原治疗近视 交联剂。 我们提供了第一个证据，证明我们的专利IVMED-85滴眼液可以诱导生化交联和 豚鼠近视眼角膜巩膜生物力学硬化与屈光度和玻璃体厚度的关系 模型(初步结果)。在这个项目中，我们将测试IVMED-85在兔身上的安全性(目标1)，并进一步阐明 树鼠停药后的疗效和持续时间，一种准灵长类动物模型。我们的计划是实现 计划进行第二阶段SBIR评估的拟议第一阶段项目的安全性和有效性的可行性结果 灵长类动物的最佳持续时间和GLP毒理学。

Project Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increasing globally at an alarming rate, with significant increases in the risks for vision impairment from pathologic conditions associated with high myopia, including retinal damage, cataract and glaucoma. In 2000, the prevalence of myopia did not exceed 50% in any of the regions but, by 2050, the prevalence will be ≥ 50% in 57% of the countries, if current trends continue. We propose a novel topical eyedrop, IVMED-85, for treating myopia. It is a first in class medication that upregulates lysyl oxidase to pharmacologically induce scleral and corneal crosslinking and stiffening. Our central hypothesis is that the topical copper eyedrop treatment may enable a non-invasive, simple to use, and relatively cost-effective treatment for myopia by pharmacologically inducing scleral and corneal collagen crosslinking. We provide the first evidence that our proprietary IVMED-85 eyedrops induce biochemical crosslinking and biomechanical stiffening in cornea and sclera and reduced refraction and vitreous depth in guinea pig myopic model (Preliminary results). In this project, we will test safety of IVMED-85 in rabbits (Aim 1) and further elucidate efficacy and duration of effect after cessation in tree shrews, a para-primate model. Our plan is to achieve the feasibility results of safety and efficacy from this proposed Phase 1 project to plan for a Phase 2 SBIR assessing optimal duration in primates and GLP toxicology.